Cargando…

Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas

INTRODUCTION: Positron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects. The interleukin-2 receptor α chain (IL-2Rα; CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Hee, Jung, Kyung-Ho, Kim, Mina, Lee, Kyung-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797992/
https://www.ncbi.nlm.nih.gov/pubmed/36591250
http://dx.doi.org/10.3389/fimmu.2022.1017132
_version_ 1784860808031764480
author Lee, Jin Hee
Jung, Kyung-Ho
Kim, Mina
Lee, Kyung-Han
author_facet Lee, Jin Hee
Jung, Kyung-Ho
Kim, Mina
Lee, Kyung-Han
author_sort Lee, Jin Hee
collection PubMed
description INTRODUCTION: Positron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects. The interleukin-2 receptor α chain (IL-2Rα; CD25) is a promising target for immune therapy and radioimmunotherapy of lymphomas. Immuno-PET could facilitate this approach by visualizing CD25 expression in vivo. METHODS: We prepared (89)Zr-anti-CD25 IgG specifically labeled to sulfhydryl moieties by maleimide-deferoxamine conjugation. RESULTS AND DISCUSSION: CD25(+) SUDHL1 human T-cell lymphoma cells showed high anti-human (89)Zr-CD25 IgG binding that reached 32-fold of that of CD25(-) human lymphoma cells and was completely blocked by excess unlabeled Ab. In SUDHL1 tumor-bearing nude mice, pharmacokinetic studies demonstrated exponential reductions of whole blood and plasma activity following intravenous (89)Zr-anti-CD25 IgG injection, with half-lives of 26.0 and 23.3 h, respectively. SUDHL1 tumor uptake of (89)Zr-CD25 IgG was lower per weight in larger tumors, but blood activity did not correlate with tumor size or blood level of human CD25, indicating minimal influence by circulating soluble CD25 protein secreted from the lymphoma cells. (89)Zr-CD25 IgG PET allowed high-contrast SUDHL1 lymphoma visualization at five days. Biodistribution studies confirmed high tumor (89)Zr-CD25 IgG uptake (8.7 ± 0.9%ID/g) that was greater than blood (5.2 ± 1.6%ID/g) and organ uptakes (0.7 to 3.5%ID/g). Tumor CD25-specific targeting was confirmed by suppression of tumor uptake to 4.3 ± 0.2%ID by excess unlabeled CD25 IgG, as well as by low tumor uptake of (89)Zr-labeled IgG2a isotype control Ab (3.6 ± 0.9%ID). Unlike CD25(+) lymphocytes from mouse thymus that showed specific uptake of anti-mouse (89)Zr-CD25 IgG, EL4 mouse lymphoma cells had low CD25 expression and showed low uptake. In immunocompetent mice bearing EL4 tumors, anti-mouse (89)Zr-CD25 IgG displayed low uptakes in normal organs as well as in the tumor. Furthermore, the biodistribution was not influenced by Ab blocking, indicating that specific uptake in nontumor tissues was minimal. (89)Zr-CD25 IgG immuno-PET may thus be useful for imaging of T-cell lymphomas and noninvasive assessment of CD25 expression on target cells in vivo.
format Online
Article
Text
id pubmed-9797992
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97979922022-12-30 Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas Lee, Jin Hee Jung, Kyung-Ho Kim, Mina Lee, Kyung-Han Front Immunol Immunology INTRODUCTION: Positron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects. The interleukin-2 receptor α chain (IL-2Rα; CD25) is a promising target for immune therapy and radioimmunotherapy of lymphomas. Immuno-PET could facilitate this approach by visualizing CD25 expression in vivo. METHODS: We prepared (89)Zr-anti-CD25 IgG specifically labeled to sulfhydryl moieties by maleimide-deferoxamine conjugation. RESULTS AND DISCUSSION: CD25(+) SUDHL1 human T-cell lymphoma cells showed high anti-human (89)Zr-CD25 IgG binding that reached 32-fold of that of CD25(-) human lymphoma cells and was completely blocked by excess unlabeled Ab. In SUDHL1 tumor-bearing nude mice, pharmacokinetic studies demonstrated exponential reductions of whole blood and plasma activity following intravenous (89)Zr-anti-CD25 IgG injection, with half-lives of 26.0 and 23.3 h, respectively. SUDHL1 tumor uptake of (89)Zr-CD25 IgG was lower per weight in larger tumors, but blood activity did not correlate with tumor size or blood level of human CD25, indicating minimal influence by circulating soluble CD25 protein secreted from the lymphoma cells. (89)Zr-CD25 IgG PET allowed high-contrast SUDHL1 lymphoma visualization at five days. Biodistribution studies confirmed high tumor (89)Zr-CD25 IgG uptake (8.7 ± 0.9%ID/g) that was greater than blood (5.2 ± 1.6%ID/g) and organ uptakes (0.7 to 3.5%ID/g). Tumor CD25-specific targeting was confirmed by suppression of tumor uptake to 4.3 ± 0.2%ID by excess unlabeled CD25 IgG, as well as by low tumor uptake of (89)Zr-labeled IgG2a isotype control Ab (3.6 ± 0.9%ID). Unlike CD25(+) lymphocytes from mouse thymus that showed specific uptake of anti-mouse (89)Zr-CD25 IgG, EL4 mouse lymphoma cells had low CD25 expression and showed low uptake. In immunocompetent mice bearing EL4 tumors, anti-mouse (89)Zr-CD25 IgG displayed low uptakes in normal organs as well as in the tumor. Furthermore, the biodistribution was not influenced by Ab blocking, indicating that specific uptake in nontumor tissues was minimal. (89)Zr-CD25 IgG immuno-PET may thus be useful for imaging of T-cell lymphomas and noninvasive assessment of CD25 expression on target cells in vivo. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9797992/ /pubmed/36591250 http://dx.doi.org/10.3389/fimmu.2022.1017132 Text en Copyright © 2022 Lee, Jung, Kim and Lee https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lee, Jin Hee
Jung, Kyung-Ho
Kim, Mina
Lee, Kyung-Han
Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
title Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
title_full Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
title_fullStr Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
title_full_unstemmed Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
title_short Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
title_sort cysteine-specific (89)zr-labeled anti-cd25 igg allows immuno-pet imaging of interleukin-2 receptor-α on t cell lymphomas
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797992/
https://www.ncbi.nlm.nih.gov/pubmed/36591250
http://dx.doi.org/10.3389/fimmu.2022.1017132
work_keys_str_mv AT leejinhee cysteinespecific89zrlabeledanticd25iggallowsimmunopetimagingofinterleukin2receptoraontcelllymphomas
AT jungkyungho cysteinespecific89zrlabeledanticd25iggallowsimmunopetimagingofinterleukin2receptoraontcelllymphomas
AT kimmina cysteinespecific89zrlabeledanticd25iggallowsimmunopetimagingofinterleukin2receptoraontcelllymphomas
AT leekyunghan cysteinespecific89zrlabeledanticd25iggallowsimmunopetimagingofinterleukin2receptoraontcelllymphomas